Achieving zero asthma-related hospitalisations in the world´s first SABA-free Asthma Center in Argentina

Click to increase image sizeClick to decrease image size

Acknowledgements

Writing and editorial support was provided by Saurabh Gagangras of Cactus Life Sciences (part of Cactus Communications, Mumbai, India) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3) and was supported by AstraZeneca. The authors thank the hospital staff who participated in this program.

Declaration of interest

LJN has received personal fees as a speaker for Novartis and AstraZeneca, fees for participating in an advisory board from Sanofi Genzyme and AstraZeneca, and personal fees to travel to meetings from Boehringer Ingelheim and AstraZeneca. OMF has received personal fees as a speaker for AstraZeneca and fees to travel to meetings from Teva Pharmaceuticals and AstraZeneca. NB does not have any conflicts of interest.

Funding

The writing support was funded by AstraZeneca; however, the company had no intellectual input in the article.

Author contributions

LJN developed the study concept and design. NB and OMF assisted in revising the source data and in the interpretation of the results, reviewed the manuscript, and provided final approval. LJN and NB contributed to the original survey design, drafted the analysis plan, carried out the statistical analysis and drafted and edited the manuscript. OMF contributed to the analysis plan and edited the manuscript. All authors approved the final manuscript for submission.